Abstract
Background Randomised Evaluation of COVID-19 Therapy (RECOVERY) demonstrated that tocilizumab reduces mortality in hospitalized COVID-19 patients. However, substantial uncertainty remains whether tocilizumab’s effect is similar across clinically relevant subgroups. Whether this uncertainty can be resolved with Bayesian methods is unknown.
Design, Setting, Participants, and Interventions RECOVERY was a controlled, open-label, platform UK trial that randomized (1:1) 4116 adults with oxygen saturation <92% on room air or receiving oxygen therapy with C-reactive protein ≥75 mg/L to either usual care or tocilizumab plus usual care.
Main outcome measures Mortality and hospital discharge within 28 days.
Methods Using Bayesian methods, we combined RECOVERY with evidence-based priors in-corporating previous COVID-19 tocilizumab RCTs. The probability of tocilizumab’s benefit for respiratory support and corticosteroid subgroups and sensitivity analyses were performed with different prior distributions and baseline risks.
Results For all-cause mortality, the posterior probabilities of decreased deaths with tocilizumab were >99% and 19% in patients using and not using corticosteroids, respectively. In patients on simple oxygen only, non-invasive ventilation and invasive mechanical ventilation, the probabilities of decreased mortality were 96%, >99% and 77%, respectively. The probabilities for a clinically significant mortality reduction, as assessed by an absolute risk difference > 3% (number needed to treat ≤ 33), were 77%, 96%, 56%, respectively. Sensitivity analyses highlighted the uncertainty and lack of conclusive evidence for tocilizumab’s effect in patients on invasive mechanical ventilation and those without concurrent corticosteroids. Posterior probabilities of benefit for hospital discharge outcome were high and consistent across most subgroups.
Conclusions In this Bayesian reanalysis, COVID-19 hospitalized patients exposed to corticosteroids or on non-invasive ventilation have a high probability of a clinically meaningful mortality benefit from tocilizumab. Tocilizumab also likely improves discharge from hospital in most subgroups. Future research should further address if patients on invasive mechanical ventilation can also benefit from tocilizumab.
Competing Interest Statement
LT participated as a sub-investigator of the TOCIBRAS, a trial considered and excluded during our data extraction process.
Clinical Trial
This is reanalysis of a previously published randomized controlled trial (NCT04381936)
Clinical Protocols
Funding Statement
Funding: JMB is a research scholar supported by Les Fonds de Recherche Québec Santé which had no influence on the choice of topic, the results or conclusions. Role of the funding source: There was no specific funding dedicated to this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was exempt from obtaining formal institutional review board approval and the requirement to obtain informed patient consent because it is secondary research of publicly available data sets.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: JMB is a research scholar supported by Les Fonds de Recherche Québec Santé which had no influence on the choice of topic, the results or conclusions.
Role of the funding source: There was no specific funding dedicated to this project.
Data Availability
The data and full analysis code are available at https://bit.ly/3xnTJSV.
